Indications
Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia. Zostavax is indicated for immunisation of individuals 50 years of age or older.
Composition
- Active substance
- varicella-zoster virus (live, attenuated)
- International name (INN)
- shingles (herpes zoster) vaccine (live)
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zostavax
- Active substance
- varicella-zoster virus (live, attenuated)
- ATC code
- J07BK02
- Therapeutic area
- Herpes Zoster, Immunization